| Symbol
| TFF3
| contributors: mct - updated : 25-10-2010
|
| HGNC name
| trefoil factor 3 (intestinal)
|
| HGNC id
| 11757
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in gastric cancer | | tumoral
|
|
| --over
|
| |
during inflammatory processes and cancer progression | | tumoral
|
|
| --over
|
| |
overexpression in hepatocellular carcinogenesis, and the specific promoter CpG hypomethylation may be one of the regulation mechanisms of TFF3 overexpression | | tumoral
|
|
| --over
|
|
by hypomethylation of the promoter/enhancer region, significantly lower in prostate carcinoma compared to benign prostatic hyperplasia  | | tumoral
|
|
| --low
|
| |
in follicular neoplastic lesions compared with that in normal thyroid tissue samples | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| overexpression and promoter hypomethylation of trefoil factors may serve as biomarkers in prostate carcinoma | |
novel serum marker for early detection and/or monitoring of poorly differentiated endometrioid endometrial carcinomas (G3-EEC) patients | |
TFF2 and probably also TFF3 are candidate biomarkers for nephrolithiasis and possibly other inflammatory conditions of the urinary tract | | Therapy target
| having broad implications for developing novel therapeutic strategies for treating nonhealing wounds | |
|
| System | Type | Disorder | Pubmed |
|---|
| immunology | autoimmune | digestive | |
| may have therapeutic potential in the treatment of inflammatory bowel disease, and one of the mechanisms may related to inhibit the TLR4/NF-kappaB signaling pathways |
| |
|
| Tff3-deficient (Tff3(-)(/)(-)) mice (Paulsen, 2008) | |
Tff3 knock-out animals show an accelerated presbyacusis and a hearing loss of about 15 dB at low frequencies increasing to 25 dB loss at higher frequencies |